Actively Recruiting
CLABSI Prevention With Tissue Adhesive
Led by Rabin Medical Center · Updated on 2024-10-02
600
Participants Needed
1
Research Sites
182 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Our aim is to test the effect of tissue adhesive application at the Central-line exit-site on CLABSI rates in high-risk pediatric congenital heart disease patients.
CONDITIONS
Official Title
CLABSI Prevention With Tissue Adhesive
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients admitted to pediatric cardiac ICU considered high-risk for CLABSI
- Age under 18 years
- Young age less than 1 year and Congenital Heart Surgery Mortality Category (STAT/STS-EACTS) score 2-5
- Risk Adjustment for Congenital Heart Surgery (RACHS) category 3 or higher
- Preoperative length of stay longer than 7 days
- Preoperative ventilator support
- Presence of a genetic abnormality
- Extracorporeal membrane oxygenation (ECMO) support
You will not qualify if you...
- Patients with ongoing bacteremia
- Patients with pre-existing central-line or peripherally inserted central catheter (PICC)
- Parental refusal to participate
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Schneider's children medical center
Petah Tikva, Israel
Actively Recruiting
Research Team
E
Eran Shostak, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here